- Home
- PRPO vs ATYR Comparison
PRPO vs ATYR Comparison
Compare PRPO & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRPO | ATYR |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.0M | 49.2M |
| IPO Year | 2000 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PRPO | ATYR |
|---|---|---|
| Price | $23.21 | $0.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $2.86 |
| AVG Volume (30 Days) | 84.8K | ★ 3.0M |
| Earning Date | 11-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.15 | 6.98 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,049,000.00 | $190,000.00 |
| Revenue This Year | $233.72 | N/A |
| Revenue Next Year | $22.61 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 29.77 | N/A |
| 52 Week Low | $16.40 | $0.25 |
| 52 Week High | $33.63 | $1.11 |
Technical Indicators
Market Signals| Indicator | PRPO | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 20.74 |
| Support Level | $22.09 | N/A |
| Resistance Level | $24.95 | $0.59 |
| Average True Range (ATR) | 1.18 | 0.03 |
| MACD | -0.11 | -0.00 |
| Stochastic Oscillator | 18.10 | 1.12 |
Price Performance
Historical ComparisonAbout PRPO Precipio Inc.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).